🎄Holiday Notice: Shipping for temperature-sensitive medications (Ozempic, Mounjaro, etc.) is paused. Service resumes Monday, Dec 29.
Generic Semaglutide Now Available!
We Ship To The U.S. Only
Call Toll Free:
Retatrutide is a new investigational weight loss and type 2 diabetes medication. It triggers activity at both the GLP-1 and GIP receptors. It is also a glucagon receptor agonist. This medication helps patients reduce their weight with delayed gastric emptying. It also helps them improve their glycemic control and metabolism. Proper dosing of this medication is important for managing side effects and getting the most effectiveness out of the medication. This article will cover this. Patients should note that current dosage charts are based on current trial data and early clinical insights – not yet final prescribing guidance
10% OFF
On Your First Order
Copy Code
MYRX10
This medication is designed to help with insulin secretion and regulate glucose production. It can also help patients manage their weight by slowing gastric emptying and helping with appetite control. This medication is still in Phase 3 clinical trials and has not yet been officially approved as of 2025. However, Phase 2 studies showed that this medication helped patients lose an average of 24.2% of their weight within 48 weeks of taking the medication.
Retatrutide is similar to other popular medications – like semaglutide (Ozempic/Wegovy) and tirzepatide (Mounjaro/Zepbound). Semaglutide medications are also GLP-1 medications. However, they are not GIP and glucagon receptor agonists. Tirzepatide works by triggering activity at both the GLP-1 and GIP receptors. This makes it a dual agonist. Retatrutide is a triple agonist that is also a glucagon receptor agonist.
| Titration Phase | Weeks | Dosage Per Week (mg) |
|---|---|---|
| Starting Dose | 1–4 | 1–2 |
| First Escalation | 5–8 | 4 |
| Second Escalation | 9–12 | 6 |
| Third Escalation | 13–16 | 8 |
| Maintenance Dose | 17+ | 8–12 |
These doses are based on what was used in trials so far. These doses may change upon further studies and the medication’s official approval. Maintenance doses may be 8 mg or 12 mg once per week depending on how the patient is tolerating and responding to the doses.
The gradual dose escalation for retatrutide is done to give patients time to adjust to the medication and reduce their chances of experiencing gastrointestinal side effects. This is why patients usually stay on a dose for at least a few weeks before having their dose increased by a couple more milligrams. This is similar to how other GLP-based medications prescribe their doses.
The gradual titration process over a period of several weeks has proven to be more tolerable for patients in other clinical trials for similar medication types. It reduces the likelihood of side effects such as nausea and stomach upset. Retatrutide is also similar to other GLP-1-based therapies in that it comes in the form of a weekly injection.
Higher doses of the medication have been observed in clinical trials to help patients lose more weight. The Phase 2 trial reported that participants experienced the following average weight loss with retatrutide at 24 weeks:
The mean weight loss increased even more at 48 weeks.
The majority of participants taking retatrutide experienced significant weight loss compared with those receiving a placebo after 48 weeks. Almost all participants taking 8 mg or 12 mg experienced a weight loss of at least 5% of their body weight. 92% of those on 4 mg did the same – compared to just 27% in the placebo group. About 60% of people on 4 mg and 75% on 8 mg lost 15% or more of their body weight. 83% of patients also lost at least 15% of their weight on 12 mg. This is much more than the 2% who lost this much when taking the placebo.
The results patients will receive from using this medication may vary depending on factors such as their baseline weight and how long they stay on the treatment. It may also be affected by their dosage and tolerance. The investigational outcomes received from the trials done so far may be different from how the drug affects patients once it has been approved and put on the market.
The exact dosing a patient is prescribed may vary for a few different reasons. Doses of this medication may vary based on what it is being used for. For example, if it is being used for glucose control or if its primary use will be for weight loss. The dose of the medication may also be adjusted based on how the patient is tolerating it. Patients who begin to experience side effects – like nausea or GI discomfort – may be put on lower doses that are easier to tolerate.
Doctors may make adjustments to the medication based on other medications that the patient is taking. This may include medications that may have interactions or if they are on an overlapping GLP-1 therapy. Doctors may also make adjustments to the dosing or recommend a different medication if the patient has certain medical conditions. This might include conditions such as kidney or liver issues. It might also include cardiovascular risk factors or metabolic disorders.
Retatrutide is designed to be used as a once-weekly injection and missing a dose of this medication can delay its steady-state effect. The medication should be taken as soon as possible if the patient realizes they have missed their dose within four days of when it was supposed to be taken. The rest of their schedule should continue as normal.
Patients should skip the dose that they missed if it has been more than four days since the time it was supposed to be taken. The next scheduled injection should still be taken on its normal day and time. Patients should never double up or take extra medication to “catch up.”
It is important for patients to avoid skipping doses. Doing so can slow down their weight-loss progress and impact their blood sugar control. Patients should contact their doctor for further instructions before restarting in the event that more than one dose has been missed. The doctor may need to adjust the titration schedule or repeat the last tolerated dose level. Patients should never restart or adjust their own dose frequency without medical supervision.
Clinical studies found that the side effects for retatrutide are similar to those experienced by patients on GLP-1 and GIP/GLP-1 receptor agonists. GI side effects were found to be the most commonly experienced. This may include diarrhea/constipation and vomiting. The most common side effect was nausea – which was found to increase in incident rates across dose levels. Most of these side effects were mild and usually improved over time with dose adjustment or slower titration.
More rare but serious risks could be issues such as pancreatitis and gallbladder disease. Thyroid issues may also occur. These side effects have occurred in some rare cases for similar medications that are already on the market. This is why it may be best for patients with histories of pancreatitis or gallbladder disease and medullary thyroid carcinoma to avoid this medication. Patients planning to take this medication should talk to their doctor to determine the best doses for them and receive additional guidance.
Andexxa (andexanet alfa) is the approved reversal agent for both Eliquis and Xarelto. This drug works by reducing anti-Factor Xa activity and stopping bleeding. It is used to reverse the effects of anticoagulation in instances of bleeding that is uncontrolled. This can help make surgeries safer and restore normal clotting activity in the body. This medication is important and can help patients avoid life-threatening events. There may be limitations on availability in certain instances.
Doses may need to be adjusted or delayed if weekly injections are missed and a doctor instructs them to do so. Some patients may also need a dose adjustment if they are experiencing persistent GI effects. Patients should never try to make any of these adjustments on their own. This includes restarting the medication after an interruption. Patients should only be made under the guidance of a licensed healthcare provider.
FDA approval applications can not take place until the completion of Phase 3 trials (which are currently taking place). These trials are expected to be wrapped up in early 2026. It will likely take another six to 10 months after the application is received for the FDA to review it. This means that the earliest patients may see this drug approved and hitting the market would likely be in 2027. Patients should expect this medication to become available under a brand name once it is released. It is best to follow updates through healthcare providers or official trial results for updated information and more more accurate timeline once more information is released.
Retatrutide is part of the same medication family as semaglutide. They also share a similar once-weekly injection schedule and gradual dose-escalation to help patients with tolerability. However, semaglutide doses are generally much lower overall. The usual starting dose of this medication is 0.25 mg weekly, with a maximum approved dose of 2.4 mg per week.
Semaglutide works by targeting one receptor in the body – the GLP-1 receptor – which helps regulate insulin and appetite. Retatrutide goes a step further. It activates three receptors (GLP-1, GIP, and glucagon). This may lead to a broader effect on metabolism and energy use.
Tirzepatide is another once-weekly injection that works by targeting two receptors – GIP and GLP-1. This is an effective medication for weight loss and improved blood sugar control as well. However, retatrutide’s triple action may help the body burn more energy and improve fat metabolism.
The doses of this medication are also titrated and are a little higher than typical retatrutide doses. Doses usually range from 2.5 mg (for the initial dose) to 15 mg (for the maximum weekly dose). Retatrutide doses are usually between 1 mg and 12 mg.
Most patients in clinical trials started with a weekly dose of 1-2 mg. This dose is then gradually increased every few weeks to help reduce the likelihood of side effects like nausea and stomach upset.
The full titration schedule typically takes about 16 weeks. After this period, most patients move to a maintenance dose of 8 mg or 12 mg per week – depending on how well they tolerate and respond to the medication.
This will depend on the specific patient and their current treatment plan. Doctors may combine it with other diabetes medications in certain cases. However, this should only be done under a doctor’s supervision to prevent possible drug interactions.
Yes. These medications also use a once-weekly injection dose with gradual dose increases to improve tolerability. The main difference is that Retatrutide targets three metabolic receptors instead of one or two.
Patients should contact their healthcare provider if they are experiencing any side effects with their increased doses. The provider may suggest staying on the previous dose a little longer or slowing the titration schedule until symptoms improve.
Patients taking retatrutide will likely be put on a gradual titration schedule of weekly injectable doses. They should also make sure to use medical supervision during this process. This medication is still under study and specific dosing information may continue to evolve by the time it is officially approved. Patients should consult a licensed healthcare provider for more personalized guidance.
Visit MyRX Outlet to purchase affordable prescription drugs and weight loss medications from Canada.
Abouelmagd, A. A., Abdelrehim, A. M., Bashir, M. N., Abdelsalam, F., Marey, A., Tanas, Y., Abuklish, D. M., & Belal, M. M. (2025). Efficacy and safety of retatrutide, a novel GLP-1, GIP, and glucagon receptor agonist for obesity treatment: a systematic review and meta-analysis of randomized controlled trials. Baylor University Medical Center Proceedings, 38(3), 291–303. https://doi.org/10.1080/08998280.2025.2456441
Billingsley, A. (2025, June 13). 7 Things to Know About Retatrutide for Weight Loss: Dosages, Clinical Trial Results, and More. GoodRx. https://www.goodrx.com/conditions/weight-loss/retatrutide-weight-loss
Olowo-Oribi, B. A. & James, S. R. (2025, August 12). Efficacy of Tirzepatide, Retatrutide, and Semaglutide for Weight Loss in Obese Individuals Without Diabetes. The NNT. https://thennt.com/nnt/efficacy-of-tirzepatide-retatrutide-and-semaglutide-for-weight-loss-in-obese-individuals-without-diabetes/
Eldor, R., Avraham, N., Rosenberg, O., Shpigelman, M., Golan-Cohen, A., Cukierman-Yaffe, T., Merzon, E., & Buch, A. (2025). Gradual Titration of Semaglutide Results in Better Treatment Adherence and Fewer Adverse Events: A Randomized Controlled Open-Label Pilot Study Examining a 16-Week Flexible Titration Regimen Versus Label-Recommended 8-Week Semaglutide Titration Regimen. AMA. https://doi.org/10.2337/dc25-0690
Frangos, J. (2025, July 18). Retatrutide Dosage: What the Science Says, Dosing Chart, and Schedule. Amazing Meds. https://amazing-meds.com/retatrutide-dosage/
Gulzar A. (2025, October 17). Zepbound (Tirzepatide) vs. Wegovy (Semaglutide) for Weight Loss. Verywell Health.
Jastreboff, A. M., Kaplan, L. M., Frías, J. P., Wu, Q., Du, Y., Gurbuz, S., Coskun, T., Haupt, A., Milicevic, Z., & Hartman, M. L. (2023). Triple–Hormone-Receptor Agonist Retatrutide for Obesity – A Phase 2 Trial. New England Journal of Medicine, 389(6), 514–526. https://doi.org/10.1056/nejmoa2301972
Katsi, V., Koutsopoulos, G., Fragoulis, C., Dimitriadis, K., & Tsioufis, K. (2025). Retatrutide – A Game Changer in Obesity Pharmacotherapy. Biomolecules, 15(6), 796. https://doi.org/10.3390/biom15060796
Morris, C. (2024, October 7). Retatrutide Dosage: Everything You Need to Know. Nulevel Wellness Medspa. https://nulevelwellnessmedspa.com/retatrutide-dosage/
Puckey, Melisa. (2025, September 16). Retatrutide FDA Approval Status. Drugs.com. https://www.drugs.com/history/retatrutide.html
Retatrutide Dosage Guide & Titration Schedule 2025. (2025, October 15). BodySpec. https://www.bodyspec.com/blog/post/retatrutide_dosage_guide_titration_schedule_2025
ANDEXXA. (2024, March 29).. U.S. Food And Drug Administration.
Answering your DVT questions. (n.d.). XARELTO®. https://www.xarelto-us.com/en/deep-vein-thrombosis/faqs/
Bayer AG. (2018). Xarelto® Dosing Guide. https://www.xarelto.com/sites/g/files/vrxlpx171/files/2020-01/dosing-guide-xarelto-effective-protection-indications-worldwide-09-2018.pdf
Blood Thinners. (n.d.). MedlinePlus. https://medlineplus.gov/bloodthinners.html
Caporuscio, J. (2021, February 25). What to know about blood thinners and alcohol. Medical News Today. https://www.medicalnewstoday.com/articles/blood-thinners-and-alcohol
Dosing Guide for All Adult ELIQUIS Indications. (n.d.). Eliquis. https://www.eliquis.com/assets/buildeasy/us-commercial/eliquis-hcp/en/resources/pdf/Eliquis-Dosing-Guide-Desktop-Version.pdf
ELIQUIS® (apixaban) tablets. (n.d.). ELIQUIS®. https://www.eliquis.bmscustomerconnect.com/
How Much Does ELIQUIS Cost?. (2025). ELIQUIS® (apixaban). https://www.eliquis.bmscustomerconnect.com/price
How to Take ELIQUIS. (n.d.). ELIQUIS®. https://www.eliquis.bmscustomerconnect.com/vte/taking-eliquis
Kirby, S. (2025, September 23). Xarelto (rivaroxaban) and cost. Medical News Today. https://www.medicalnewstoday.com/articles/drugs-xarelto-cost
Learn more about your condition and how you could save on XARELTO®. (n.d.). Official Patient Website | XARELTO® (Rivaroxaban). https://www.xarelto-us.com/xarelto-cost/en/
Lip, G. Y. H., Keshishian, A. V., Zhang, Y., Kang, A., Dhamane, A. D., Luo, X., Klem, C., Ferri, M., Jiang, J., Yuce, H., & Deitelzweig, S. (2021). Oral Anticoagulants for Nonvalvular Atrial Fibrillation in Patients With High Risk of Gastrointestinal Bleeding. JAMA Network Open, 4(8), e2120064. https://doi.org/10.1001/jamanetworkopen.2021.20064
Mamas, M. A., Batson, S., Pollock, K. G., Grundy, S., Matthew, A., Chapman, C., Manuel, J. A., Farooqui, U., & Mitchell, S. A. (2021). Meta-Analysis Comparing Apixaban Versus Rivaroxaban for Management of Patients With Nonvalvular Atrial Fibrillation. The American Journal of Cardiology, 166, 58–64. https://doi.org/10.1016/j.amjcard.2021.11.021
Medical Advisory Board. (2025, May 2). Do apixaban (Eliquis) and rivaroxaban (Xarelto) require gastric acid for absorption? https://www.droracle.ai/articles/100567/does-apixaban-and-rivaroxaban-need-gastric-acid-to-be-absorbed
Medical Information Center. (n.d.). XARELTO® (Rivaroxaban). https://www.xareltohcp.com/medical-information-center-professional-product-sites/?utm_source=google&utm_medium=cpc&utm_campaign=EG-HCPB-BR-NA-Xarelto-JJ-Resources-Exact-Side+Effects&utm_content=Xarelto+Side+Effects-TXT-National-NA-1-EX&utm_term=xarelto+side+effects&gclsrc=aw.ds&gad_source=1&gad_campaignid=19239696658&gbraid=0AAAAADoySLoIDFggTbTlfysvpetgojVbT&gclid=CjwKCAjwx-zHBhBhEiwA7Kjq68EfJOlSUUdzbAKvExGgmBY1p2YJYtu8VkSUMOKFDQTI_edFM-gmmBoCpWcQAvD_BwE
Morgan, L., Gettings, M., & Drug & Therapeutics Committee. (2021). Guidance on Converting Between Anticoagulants. NHS. https://www.gloshospitals.nhs.uk/media/documents/Guidance_on_converting_between_anticoagulant_regimens.pdf
USC Schaeffer Center. (2025, February 14). Medicare Beneficiaries Face Much Higher Drug Costs as Plans Quickly Shift to Coinsurance. USC Alfred E. Mann School of Pharmacy and Pharmaceutical Sciences. https://mann.usc.edu/news/medicare-beneficiaries-face-much-higher-drug-costs-as-plans-quickly-shift-to-coinsurance/
Watson, A. (2022, September 19). Xarelto vs. Eliquis. https://www.medicalnewstoday.com/articles/drugs-xarelto-vs-eliquis
What Are Some Possible Serious Side Effects of ELIQUIS? (n.d.). ELIQUIS®. https://www.eliquis.bmscustomerconnect.com/afib/side-effects
XARELTO® (rivaroxaban). (n.d.). XARELTO®. https://www.xarelto-us.com/en/
Written & Reviewed By
The MyRx Team
The MyRx Outlet team is a dedicated group of healthcare professionals and pharmacists dedicated to delivering up-to-date and accurate information on medications and key healthcare topics. With years of experience in the healthcare field, our team is passionate about supporting individuals in reaching their health and wellness goals through our articles.
The information provided here is for educational purposes only and is not intended to serve as medical advice, diagnosis, or treatment recommendations. It should not be taken as an endorsement of any specific medication or treatment. Individual health conditions and responses to treatment can vary greatly; therefore, this information should not be seen as a guarantee of safety, suitability, or effectiveness for any particular individual. Always consult with a healthcare professional for personalized medical advice and before making any decisions regarding your health or treatment plans.
Related Articles
Learn about Mounjaro’s potential long-term side effects, safety insights from early research, and what patients should know before long-term use.
Sober curiosity is growing as Americans re-evaluate drinking habits for health and savings. Discover the trends and insights from our nationwide survey.
Share:
